KRYS · Krystal Biotech Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.51B |
| P/E | 39.71 |
| Float | 25.70M |
| Beta | 0.64 |
| Volatility | 16.1% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 75.0 |
| Price | 325.75 |
| Change | +1.43% |
| Prev Close | 321.16 |
| Open | 331.48 |
| Day Low | 320.95 |
| Day High | 331.93 |
| Avg Vol | 0 |
| Avg $ Vol | $90.74M |
| 52W High | 382.54 |
| 52W Low | 179.19 |
| 52W Pos | 72.1% |
| From High | −14.84% |
| From Low | +81.79% |
| Max DD 1Y | −17.34% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.47% |
| SMA 50 | −4.10% |
| SMA 200 | +7.03% |
| RSI (14) | 39.9 |
| Vol 30D | 30.3% |
| Vol 90D | 40.3% |
| 1Y Range | 179–383 |
| Daily bars | 533 |
| Perf Week | −1.73% |
| Perf Month | −5.55% |
| Perf Quarter | −8.30% |
| Perf Half Y | +18.95% |
| Perf Year | +76.98% |
| Perf YTD | +31.93% |
| Prev Day | +1.43% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 9.95 |
| Int Cover | -9.8× |
| FCF Margin | 48.5% |
| Rev Growth | +33.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 35 |
Clavix risk grade
regraded every trading dayKRYS grades B, 75.0 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (58, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 14 of 35 in Biotechnology by Clavix score.
How rough the ride is
| KRYS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.64 | 0.50 |
| Volatilityannualized | 16.1% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −17.3% | — |
| Typical daily movemedian absolute daily change | 1.43% | — |
| Days beyond ±3%of the last 252 sessions | 45 (18%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| KRYS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.64 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| KRYS | |
|---|---|
| 1 week | −1.7% |
| 1 month | −5.5% |
| Year to date | +31.9% |
| 1 year | +77.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| KRYS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 8 since 10 Aug |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 6 · 2 |
| Directionarticles whose tone is improving vs worsening | 6 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| KRYS | |
|---|---|
| Revenue growthyear over year | +33.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn analyst rates Krystal Biotech a 'Buy', citing $119.2 million in Q2 Vyjuvek revenue, a $1.1 billion cash position, a 40% operating margin, and a forward price-to-earnings ratio of about 12x as evidence the stock has not yet peaked.
Krystal Biotech's VYJUVEK gene therapy for dystrophic epidermolysis bullosa (a rare genetic condition that causes fragile, blistering skin) has delivered strong sales and high profit margins since launch. Its specialized manufacturing and recurring dosing model have built a competitive advantage, though European pricing talks and new competitors are creating uncertainty.
Krystal Biotech (KRYS) is drawing attention as its VYJUVEK gene therapy for dystrophic epidermolysis bullosa gains commercial traction, backed by high revenue, strong gross margins, and recurring treatment demand. The stock has pulled back about 9% over the past month and 13% over the past quarter, though it remains up 31.45% year-to-date and 73.40% over one year.
The article notes that Krystal Biotech's stock has risen roughly 7x over five years and now trades near $324.57, and it raises concerns about whether the company's earnings support that price. It frames the share gain as built largely on expectations rather than confirmed earnings power.
Congress Asset Management Co. grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,083 shares of the company's stock after pu
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TWST | Twist Bioscience Corp | D+ | $9.96B | — | 2.15 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.96B | 108.03 | 1.19 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.45B | — | -1.10 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.57B | — | 0.41 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.35B | 79.37 | 0.40 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.32B | 19.16 | 1.82 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.21B | — | 1.33 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.